TY - JOUR T1 - Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin JF - In Vivo JO - In Vivo SP - 2739 LP - 2743 DO - 10.21873/invivo.12096 VL - 34 IS - 5 AU - YOSHIHISA ARAKAKI AU - TAKURO ARIGA AU - JOICHI HEIANNA AU - YUKO SHIMOJI AU - TADAHARU NAKASONE AU - YUSUKE TAIRA AU - TOMOKO NAKAMOTO AU - TAKUMA OOYAMA AU - WATARU KUDAKA AU - ITOMI KANESHIMA AU - KUMIKO NISHIHIRA AU - KEIKO MEKARU AU - YOICHI AOKI Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/2739.abstract N2 - Background/Aim: We retrospectively analyzed the locally advanced adenocarcinoma (AC)/adenosquamous carcinoma (ASC) of the uterine cervix treated with concurrent chemoradiotherapy using cisplatin plus paclitaxel (TP-CCRT). Patients and Methods: Thirty patients with stage IB–IVA AC/ASC were treated with whole pelvis external beam radiotherapy. A high-dose-rate intracavitary brachytherapy was delivered once per week at a fractional dose of 6 Gy. For TP-CCRT, the patients received cisplatin and paclitaxel. Results: A complete response was achieved in 17 patients (77.3%) in the TP-CCRT group and 4 patients (50.0%) in the P-CCRT group. The 5-year OS rate in the TP-CCRT and P-CCRT groups was 74.2% and 25.0% (p=0.0094), the central DFS rate was 58.0% and 12.5% (p=0.0267), and the distant DFS rate was 63.6% and 12.5% (p=0.0042), respectively. Conclusion: TP-CCRT achieves a considerably better disease control for AC of the cervix, leading to a better OS. ER -